MCID: ORL007
MIFTS: 59

Oral Cavity Cancer

Categories: Cancer diseases, Oral diseases

Aliases & Classifications for Oral Cavity Cancer

MalaCards integrated aliases for Oral Cavity Cancer:

Name: Oral Cavity Cancer 12 14
Malignant Neoplasm of Anterior Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Floor of Mouth 12
Malignant Tumor of Anterior Floor of Mouth 12
Malignant Tumor of Lateral Floor of Mouth 12
Malignant Tumor of the Floor of the Mouth 12
Malignant Neoplasm of Floor of Mouth 12
Neoplasm of the Oral Cavity 28
Malignant Neoplasm of Mouth 69
Oral Cavity Carcinoma 69

Classifications:



Summaries for Oral Cavity Cancer

Disease Ontology : 12 A gastrointestinal system cancer that is located in the oral cavity.

MalaCards based summary : Oral Cavity Cancer, also known as malignant neoplasm of anterior portion of floor of mouth, is related to salivary gland cancer and leukoplakia. An important gene associated with Oral Cavity Cancer is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Development Endothelin-1/EDNRA signaling. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include the oral cavity, salivary gland and tongue, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Related Diseases for Oral Cavity Cancer

Diseases in the Oral Cavity Cancer family:

Oral Cavity Carcinoma in Situ

Diseases related to Oral Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 salivary gland cancer 31.9 CASP8 EGFR ERBB2 MAML2
2 leukoplakia 30.6 CYP1A1 GSTM1 GSTT1
3 lip and oral cavity cancer 12.3
4 oral squamous cell carcinoma 11.0
5 breast intraductal proliferative lesion 10.7 EGFR ERBB2
6 hearing loss, noise-induced 10.6 GSTM1 GSTT1
7 intracystic papillary adenoma 10.6 EGFR ERBB2
8 acneiform dermatitis 10.6 CYP1A1 EGFR ERBB2
9 geographic tongue 10.6 EGFR TNFRSF10B VEGFA
10 primary peritoneal carcinoma 10.6 EGFR ERBB2 VEGFA
11 progesterone-receptor negative breast cancer 10.6 EGFR ERBB2
12 endometrial adenocarcinoma 10.6 EGFR ERBB2 VEGFA
13 breast scirrhous carcinoma 10.5 EGFR ERBB2
14 oral leukoplakia 10.5 ERBB2 GSTM1 GSTT1
15 ovarian cancer 1 10.5 EGFR ERBB2 VEGFA
16 female reproductive organ cancer 10.5 EGFR ERBB2 VEGFA
17 oral submucous fibrosis 10.5 CYP1A1 GSTM1 GSTT1
18 reproductive organ cancer 10.5 EGFR ERBB2 VEGFA
19 sister chromatid exchange, frequency of 10.5 ALDH2 GSTM1 GSTT1
20 breast adenocarcinoma 10.5 CASP8 EGFR ERBB2
21 squamous cell carcinoma of the larynx 10.5 EGFR GSTM1
22 pancreatic ductal adenocarcinoma 10.5 EGFR ERBB2 VEGFA
23 gastrointestinal system cancer 10.5 EGFR ERBB2 VEGFA
24 oral cancer 10.5 CYP1A1 EGFR GSTM1 GSTT1
25 cell type cancer 10.5 EGFR ERBB2 SOX2 VEGFA
26 tumor suppressor gene on chromosome 11 10.5 EGFR ERBB2
27 malignant glioma 10.5 CASP8 EGFR TNFRSF10B VEGFA
28 glioblastoma multiforme 10.4 EGFR ERBB2 TNFRSF10B VEGFA
29 oncocytic breast carcinoma 10.4 EGFR ERBB2
30 tobacco addiction 10.4 ALDH2 GSTM1 GSTT1
31 lung cancer susceptibility 3 10.4 CASP8 CYP1A1 EGFR ERBB2 VEGFA
32 squamous cell carcinoma 10.4 CYP1A1 EGFR ERBB2 TNFRSF10B VEGFA
33 nasopharyngeal carcinoma 10.4 EGFR GSTM1 GSTT1 VEGFA
34 acute lymphocytic leukemia 10.4 GSTM1 GSTT1 MCL1
35 mucoepidermoid carcinoma 10.3 EGFR ERBB2 MAML2
36 renal cell carcinoma, nonpapillary 10.3 CASP8 EGFR TNFRSF10B VEGFA
37 isolated cleft lip 10.3 GSTM1 GSTT1
38 lung squamous cell carcinoma 10.3 CYP1A1 EGFR SOX2
39 squamous cell carcinoma, head and neck 10.3 EGFR ERBB2 GSTM1 GSTT1 TNFRSF10B VEGFA
40 bladder cancer 10.2 EGFR ERBB2 GSTM1 GSTT1 VEGFA
41 esophageal cancer 10.1 ALDH2 CYP1A1 EGFR ERBB2 GSTM1 GSTT1
42 larynx cancer 10.0 EGFR GSTM1 GSTT1
43 hepatocellular carcinoma 10.0 CASP8 CYP1A1 EGFR GSTM1 GSTT1 LIN28B
44 lung cancer 9.9 CASP8 CYP1A1 EGFR ERBB2 GSTM1 GSTT1
45 body mass index quantitative trait locus 1 9.8
46 mucositis 9.8
47 papilloma 9.8
48 prostate cancer 9.8 CASP8 EGFR ERBB2 GDF15 GSTM1 HSP90B1
49 aging 9.7
50 episodic pain syndrome, familial, 1 9.7

Comorbidity relations with Oral Cavity Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oral Cavity Cancer:



Diseases related to Oral Cavity Cancer

Symptoms & Phenotypes for Oral Cavity Cancer

GenomeRNAi Phenotypes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR ERBB2 FADD
2 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR

MGI Mouse Phenotypes related to Oral Cavity Cancer:

43 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 CASP8 CYP1A1 EGFR ERBB2 FADD GDF15
2 growth/size/body region MP:0005378 10.25 EGFR ERBB2 FADD GDF15 HSP90B1 LIN28B
3 homeostasis/metabolism MP:0005376 10.22 ALDH2 CASP8 CYP1A1 DNAJB7 EGFR ERBB2
4 endocrine/exocrine gland MP:0005379 10.16 ERBB2 FADD MCL1 SOX2 TLR2 VEGFA
5 embryo MP:0005380 10.13 CASP8 EGFR ERBB2 FADD HSP90B1 LIN28B
6 mortality/aging MP:0010768 10.1 ALDH2 CASP8 CYP1A1 EGFR ERBB2 FADD
7 digestive/alimentary MP:0005381 10.04 EGFR ERBB2 FADD SHOX2 SOX2 TLR2
8 integument MP:0010771 9.97 ALDH2 CASP8 EGFR ERBB2 MCL1 SOX2
9 liver/biliary system MP:0005370 9.92 ALDH2 CASP8 CYP1A1 EGFR FADD GDF15
10 muscle MP:0005369 9.76 CASP8 EGFR ERBB2 FADD LIN28B SOX2
11 neoplasm MP:0002006 9.5 TLR2 VEGFA ALDH2 CASP8 EGFR ERBB2
12 nervous system MP:0003631 9.36 GDF15 LIN28B SHOX2 SOX2 TLR2 VEGFA

Drugs & Therapeutics for Oral Cavity Cancer

Drugs for Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 385)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1 51-43-4 5816
2 Racepinephrine Approved Phase 4,Phase 2,Phase 1 329-65-7
3
Norepinephrine Approved Phase 4 51-41-2 439260
4
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
5
Nicotine Approved Phase 4 54-11-5 89594 942
6
Bupropion Approved Phase 4,Phase 2 34911-55-2, 34841-39-9 444
7
Dobutamine Approved Phase 4 34368-04-2 36811
8 Dopexamine Approved, Investigational Phase 4 86197-47-9 55483
9
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
10 Respiratory System Agents Phase 4,Phase 2
11 Adrenergic Agents Phase 4,Phase 2,Phase 3
12 Adrenergic Agonists Phase 4,Phase 2,Phase 3
13 Chelating Agents Phase 4,Early Phase 1
14 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3
15 Mydriatics Phase 4,Phase 2
16 Adrenergic beta-Agonists Phase 4,Phase 2
17 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Early Phase 1
18 Vasoconstrictor Agents Phase 4,Phase 2,Phase 1
19 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
20 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
21 Anti-Asthmatic Agents Phase 4,Phase 2
22 Epinephryl borate Phase 4,Phase 2,Phase 1
23 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
25 Radiopharmaceuticals Phase 4,Phase 1,Phase 2
26 Autonomic Agents Phase 4,Phase 3,Phase 2
27 Bronchodilator Agents Phase 4,Phase 2
28 Dopamine agonists Phase 4
29 Central Nervous System Stimulants Phase 4,Phase 3
30 Cholinergic Agents Phase 4,Phase 3,Phase 2
31 Technetium Tc 99m Sulfur Colloid Phase 4
32 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
33 Nicotinic Agonists Phase 4
34 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
35 Vasodilator Agents Phase 4
36 Dopamine Agents Phase 4,Phase 2
37 Dopamine Uptake Inhibitors Phase 4,Phase 2
38 Antidepressive Agents Phase 4,Phase 3,Phase 2
39 Antidepressive Agents, Second-Generation Phase 4,Phase 2
40 Psychotropic Drugs Phase 4,Phase 3,Phase 2
41 Technetium Tc 99m Pentetate Phase 4
42 Dextrans Phase 4
43 Pentetic Acid Phase 4
44 Anticoagulants Phase 4
45 Plasma Substitutes Phase 4
46 Blood Substitutes Phase 4
47
Ethanol Approved Phase 3,Early Phase 1 64-17-5 702
48
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
49
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 2767 441203 84093
50
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142

Interventional clinical trials:

(show top 50) (show all 531)

# Name Status NCT ID Phase Drugs
1 Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Unknown status NCT00172965 Phase 4
2 Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
3 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
5 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
6 The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Recruiting NCT03017053 Phase 4
7 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Active, not recruiting NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
8 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
9 Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Unknown status NCT00655421 Phase 3
10 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
11 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
12 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
13 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
14 Trial of IIb Preserving Neck Dissection Unknown status NCT00847717 Phase 3
15 The Feasibility of Dexmedetomidine for Awake Fiberoptic Nasal Intubation Unknown status NCT00815893 Phase 2, Phase 3 dexmedetomidine;Normal Saline 0.9%;propofol 1%
16 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
17 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
18 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
19 Workplace Tobacco Cessation And Oral Cancer Screening Study Completed NCT00750503 Phase 3
20 Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
21 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Completed NCT01265849 Phase 3
22 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
23 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
24 Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Completed NCT00201279 Phase 3 13-cis Retino Acid
25 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
26 Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Completed NCT00359645 Phase 3
27 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
28 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
29 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
30 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
31 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
32 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
33 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
34 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
35 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
36 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
37 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
38 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
39 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
40 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
41 The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome Completed NCT01414790 Phase 3
42 Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Recruiting NCT00964977 Phase 3
43 DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer Recruiting NCT03237325 Phase 3 SGX942;Placebo
44 Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers Recruiting NCT02868151 Phase 2, Phase 3 Ascorbic Acid;Zinc acetate
45 Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Recruiting NCT02236936 Phase 3 Cisplatin
46 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Recruiting NCT00956007 Phase 3
47 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Recruiting NCT02048254 Phase 3
48 Erlotinib Prevention of Oral Cancer (EPOC) Active, not recruiting NCT00402779 Phase 3 Erlotinib;Placebo
49 IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Active, not recruiting NCT00158678 Phase 3 concomitant cisplatin
50 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil

Search NIH Clinical Center for Oral Cavity Cancer

Genetic Tests for Oral Cavity Cancer

Genetic tests related to Oral Cavity Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Oral Cavity 28

Anatomical Context for Oral Cavity Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Oral Cavity Cancer:

18
The Oral Cavity

MalaCards organs/tissues related to Oral Cavity Cancer:

38
Salivary Gland, Tongue, Lung, Lymph Node, Breast, Brain, Skin

Publications for Oral Cavity Cancer

Articles related to Oral Cavity Cancer:

(show top 50) (show all 285)
# Title Authors Year
1
Association of Time between Surgery and Adjuvant Therapy with Survival in Oral Cavity Cancer. ( 29313448 )
2018
2
Genetic analysis of surgical margins in oral cavity cancer. ( 29341160 )
2018
3
The effectiveness of a saline mouth rinse regimen and education programme on radiation-induced oral mucositis and quality of life in oral cavity cancer patients: A randomised controlled trial. ( 29315944 )
2018
4
Conditional relative survival of oral cavity cancer: Based on Korean Central Cancer Registry. ( 28797465 )
2017
5
Estimating Survival After Salvage Surgery for Recurrent Oral Cavity Cancer. ( 28448645 )
2017
6
Frequency of Depression and its Correlation with Quality of Life of Patients with Oral Cavity Cancer. ( 28883770 )
2017
7
Treatment outcome of advance staged oral cavity cancer: concurrent chemoradiotherapy compared with primary surgery. ( 28321535 )
2017
8
Comparison of Selected Protein Levels in Tumour and Surgical Margin in a Group of Patients with Oral Cavity Cancer. ( 28421310 )
2017
9
What additional treatment is indicated for oral cavity cancer with isolated perineural invasion? ( 28349551 )
2017
10
Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis. ( 28426848 )
2017
11
Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer. ( 28838425 )
2017
12
Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer. ( 28880746 )
2017
13
Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. ( 28797467 )
2017
14
Factors associated with continued smoking after treatment of oral cavity cancer: An age and survival time-matched study. ( 29148210 )
2017
15
Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. ( 28806994 )
2017
16
Untreated oral cavity cancer: Long-term survival and factors associated with treatment refusal. ( 28865100 )
2017
17
Coinfection with Epstein-Barr Virus (EBV), Human Papilloma Virus (HPV) and Polyoma BK Virus (BKPyV) in Laryngeal, Oropharyngeal and Oral Cavity Cancer. ( 29257122 )
2017
18
Comparison of facility type outcomes for oral cavity cancer: Analysis of the national cancer database. ( 28671267 )
2017
19
Surgical site infections following oral cavity cancer resection and reconstruction is a risk factor for plate exposure. ( 28390434 )
2017
20
Prognostic implication of ERCC1 protein expression in resected oropharynx and oral cavity cancer. ( 28645807 )
2017
21
Primary Surgery vs Radiotherapy for Early Stage Oral Cavity Cancer. ( 29256326 )
2017
22
Quality Metrics in Oral Cavity Cancer-Developing Standards for Optimal Lymph Node Yield. ( 28715525 )
2017
23
Influence of time interval from diagnosis to treatment on survival for oral cavity cancer: A nationwide cohort study. ( 28388649 )
2017
24
Recent Trends in Oral Cavity Cancer Research Support in the United States. ( 28033064 )
2017
25
Chronic Opioid Use Following Surgery for Oral Cavity Cancer. ( 28445584 )
2017
26
Pathological features and their prognostic impacts on oral cavity cancer patients among different subsites - A singe institute's experience in Taiwan. ( 28785002 )
2017
27
Quality of Life of Patients with Oral Cavity Cancer. ( 28484351 )
2017
28
Neck dissection and stroke in patients with oral cavity cancer: A population-based cohort study. ( 27439202 )
2016
29
High-Volume Surgeons Deliver Larger Surgical Margins in Oral Cavity Cancer. ( 26896758 )
2016
30
CT Accuracy of Extrinsic Tongue Muscle Invasion in Oral Cavity Cancer. ( 28059707 )
2016
31
Individualized risk prediction of outcomes for oral cavity cancer patients. ( 27939002 )
2016
32
Prognostic value of glucosylceramide synthase and P-glycoprotein expression in oral cavity cancer. ( 27000845 )
2016
33
Electronic Cigarette: Role in the Primary Prevention of Oral Cavity Cancer. ( 27773997 )
2016
34
Identification of High-Risk Subgroups of Patients With Oral Cavity Cancer in Need of Postoperative Adjuvant Radiotherapy or Chemo-Radiotherapy. ( 27258508 )
2016
35
Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. ( 28006086 )
2016
36
Cost-Effectiveness Analysis of Elective Neck Dissection in Patients With Clinically Node-Negative Oral Cavity Cancer. ( 27551113 )
2016
37
Impact of postoperative daily image-guided intensity-modulated radiotherapy on overall and local progression-free survival in patients with oral cavity cancer. ( 26906330 )
2016
38
Validity and reliability of the Korean version of the Speech Handicap Index in patients with oral cavity cancer. ( 26701323 )
2016
39
Decreasing loco-regional recurrence for oral cavity cancer with total Mohs margins technique. ( 27906094 )
2016
40
Estrogen and Progesterone hormone receptor expression in oral cavity cancer. ( 27475696 )
2016
41
Trends in oral cavity cancer incidence, mortality, survival and treatment in the Netherlands. ( 27038013 )
2016
42
Submental island flap reconstruction in oral cavity cancer patients with level I lymph node metastasis. ( 27876545 )
2016
43
Impact of microsatellite alteration in surgical margins on local recurrence in oral cavity cancer patients. ( 27430224 )
2016
44
How does depth of invasion influence the decision to do a neck dissection in clinically N0 oral cavity cancer? ( 26666561 )
2016
45
Outcome of operable oral cavity cancer and impact of maintenance metronomic chemotherapy: A retrospective study from rural India. ( 27275446 )
2016
46
Human Papilloma Virus in Oral Cavity Cancer and Relation to Change in Quality of Life Following Treatment-a Pilot Study from Northern India. ( 27872524 )
2016
47
HPV prevalence and p16INKa overexpression in non smoking non drinking oral cavity cancer patients. ( 26993152 )
2016
48
Increasing use of nonsurgical therapy in advanced-stage oral cavity cancer: A population-based study. ( 27641220 )
2016
49
Designing and Dosimetry of a Shield for Photon Fields of Radiation Therapy in Oral Cavity Cancer. ( 26120570 )
2015
50
Beneficial impact of multidisciplinary team management on the survival in different stages of oral cavity cancer patients: results of a nationwide cohort study in Taiwan. ( 25484134 )
2015

Variations for Oral Cavity Cancer

ClinVar genetic disease variations for Oral Cavity Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
2 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904

Expression for Oral Cavity Cancer

Search GEO for disease gene expression data for Oral Cavity Cancer.

Pathways for Oral Cavity Cancer

Pathways related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.58 CASP8 EGFR FADD HSP90B1 MAML2 MCL1
2
Show member pathways
12.52 CASP8 EGFR FADD TNFRSF10B VEGFA
3
Show member pathways
12.5 CASP8 FADD TLR2 TNFRSF10B VEGFA
4 12.28 CASP8 EGFR ERBB2 FADD GSTM1 GSTT1
5
Show member pathways
12.19 CASP8 FADD HSP90B1 TLR2
6 12.16 EGFR ERBB2 TLR2 VEGFA
7 12.09 GDF15 LIN28B MAML2 SOX2
8 11.99 CASP8 FADD GDF15 MCL1 TNFRSF10B
9 11.98 CASP8 EGFR FADD VEGFA
10 11.9 GSTM1 GSTT1 HSP90B1 VEGFA
11 11.85 EGFR GDF15 MCL1 TNFRSF10B
12 11.78 EGFR ERBB2 VEGFA
13 11.76 HSP90B1 MCL1 SOX2 VEGFA
14
Show member pathways
11.75 CASP8 EGFR ERBB2 HSP90B1 TLR2
15
Show member pathways
11.74 EGFR ERBB2 VEGFA
16
Show member pathways
11.69 CASP8 FADD MCL1
17
Show member pathways
11.66 CYP1A1 GSTM1 GSTT1
18 11.62 EGFR ERBB2 VEGFA
19 11.37 CYP1A1 EGFR VEGFA
20 11.28 CASP8 FADD TNFRSF10B
21 10.92 CYP1A1 GSTM1 GSTT1
22 10.88 CASP8 ERBB2 FADD GSTM1 GSTT1

GO Terms for Oral Cavity Cancer

Cellular components related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.56 CASP8 EGFR FADD TLR2
2 cell body GO:0044297 9.5 CASP8 FADD TLR2
3 ripoptosome GO:0097342 9.16 CASP8 FADD
4 death-inducing signaling complex GO:0031264 8.96 CASP8 FADD
5 CD95 death-inducing signaling complex GO:0031265 8.62 CASP8 FADD

Biological processes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.8 CASP8 FADD GDF15 MCL1 TNFRSF10B
2 response to lipopolysaccharide GO:0032496 9.78 CASP8 CYP1A1 TLR2 TNFRSF10B
3 response to hypoxia GO:0001666 9.73 CYP1A1 HSP90B1 TLR2 VEGFA
4 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.72 CASP8 FADD TNFRSF10B
5 positive regulation of epithelial cell proliferation GO:0050679 9.69 EGFR ERBB2 VEGFA
6 positive regulation of MAP kinase activity GO:0043406 9.67 EGFR ERBB2 VEGFA
7 cell surface receptor signaling pathway GO:0007166 9.65 CASP8 EGFR ERBB2 FADD TNFRSF10B
8 negative regulation of ERBB signaling pathway GO:1901185 9.58 EGFR ERBB2
9 positive regulation of macrophage differentiation GO:0045651 9.58 CASP8 FADD
10 activation of cysteine-type endopeptidase activity GO:0097202 9.57 CASP8 FADD
11 regulation of necroptotic process GO:0060544 9.56 CASP8 FADD
12 toll-like receptor 3 signaling pathway GO:0034138 9.54 CASP8 FADD
13 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.54 CASP8 FADD TNFRSF10B
14 death-inducing signaling complex assembly GO:0071550 9.52 CASP8 FADD
15 cellular response to mechanical stimulus GO:0071260 9.46 CASP8 EGFR FADD TNFRSF10B
16 TRAIL-activated apoptotic signaling pathway GO:0036462 9.32 CASP8 FADD
17 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.13 CASP8 FADD TNFRSF10B
18 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 8.8 CASP8 FADD TNFRSF10B
19 positive regulation of transcription by RNA polymerase II GO:0045944 10 EGFR FADD MAML2 SHOX2 SOX2 TLR2

Molecular functions related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.65 EGFR ERBB2 MCL1 TLR2 VEGFA
2 protein phosphatase binding GO:0019903 9.33 EGFR ERBB2 HSP90B1
3 death receptor binding GO:0005123 9.32 CASP8 FADD
4 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.96 EGFR ERBB2
5 death effector domain binding GO:0035877 8.62 CASP8 FADD

Sources for Oral Cavity Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....